Integra LifeSciences Holdings CorporationIARTNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average, modest growth trend.
Left:
||||
Year-over-year research & development expense growth
Latest
-16.82%
↓ 929% below average
Average (39q)
2.03%
Historical baseline
Range
High:38.36%
Low:-28.30%
CAGR
+9.3%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | -16.82% |
| Q2 2025 | 9.18% |
| Q1 2025 | -20.77% |
| Q4 2024 | 13.76% |
| Q3 2024 | -7.83% |
| Q2 2024 | 10.39% |
| Q1 2024 | 11.04% |
| Q4 2023 | -8.69% |
| Q3 2023 | 0.03% |
| Q2 2023 | -0.51% |
| Q1 2023 | -0.22% |
| Q4 2022 | 8.28% |
| Q3 2022 | -3.33% |
| Q2 2022 | 6.24% |
| Q1 2022 | -2.59% |
| Q4 2021 | -4.28% |
| Q3 2021 | 28.38% |
| Q2 2021 | -10.07% |
| Q1 2021 | 0.88% |
| Q4 2020 | 13.97% |
| Q3 2020 | 30.38% |
| Q2 2020 | -28.30% |
| Q1 2020 | -20.83% |
| Q4 2019 | 38.36% |
| Q3 2019 | 7.77% |
| Q2 2019 | -3.76% |
| Q1 2019 | -9.74% |
| Q4 2018 | -0.05% |
| Q3 2018 | 6.29% |
| Q2 2018 | 4.27% |
| Q1 2018 | 6.66% |
| Q4 2017 | 14.27% |
| Q3 2017 | -4.53% |
| Q2 2017 | 1.63% |
| Q1 2017 | 11.46% |
| Q4 2016 | -8.09% |
| Q3 2016 | 3.03% |
| Q2 2016 | 1.58% |
| Q1 2016 | 4.22% |
| Q4 2015 | -0.52% |